Eupraxia Pharmaceuticals Gets FDA Fast-Track Designation for EP-104IAR Study
13 6월 2023 - 8:43PM
Dow Jones News
By Robb M. Stewart
Eupraxia Pharmaceuticals said Tuesday the U.S. Food and Drug
Administration has granted fast-track designation for the
investigation of the company's lead product candidate, EP-104IAR,
in the treatment of adults with osteoarthritis of the knee.
The clinical-stage biotechnology company said it continues to
advance its ongoing Phase 2 trial evaluating EP-104IAR's safety and
efficacy as a treatment candidate for knee osteoarthritis and
expects to report top-line data results in the second quarter of
this year.
The FDA's fast-track process is designed to help the development
and speed the review of drugs that treat serious conditions and
fill an unmet medical need.
In late May, Eupraxia said it reached the last patient to visit
in its Phase 2 clinical trial of EP-104IAR for osteoarthritis,
milestone toward the completion of the study.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
June 13, 2023 07:28 ET (11:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Eupraxia Pharmaceuticals (TSX:EPRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Eupraxia Pharmaceuticals (TSX:EPRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
